Formulation Development

The primary characteristic of Containment Isolators is maximizing operator protection: Tema Sinergie Containment Isolator systems have been designed for handling high potent compounds and offer guaranteed very high levels of user protection.

The THUNDER Imager Tissue allows real-time fluorescence imaging of 3D tissue sections typically used in neuroscience and histology research. Acquire rich, detailed images of thick tissues free of haze from out-of-focus blur.

Even fine structures deep in tissues can be resolved thanks to Computational Clearing, an innovative Leica technology. Image detailed morphological structures like axons and dendrites of neurons in a brain slice. The high image quality, even with thick tissue sections, is combined with the well-known speed, fluorescence efficiency, and ease of use of widefield microscopes.

Observe the viability of your cells with the field-upgradeable cellular imaging option for the SpectraMax i3/i3x Multi-mode Detection Platform.

Curia’s DMPK scientists deliver expert solutions for your drug discovery programs. Providing bioanalytical methods development, in vitro ADMET testing and in vivo PK and PD services that span all stages of drug discovery up to candidate selection.

The systems can be provided in sterile, toxic or sterile toxic arrangements with the great advantage of being 100 % scalable.

The 3D Ready™ Organoid Expansion Service provides researchers with large numbers of high quality, low-variability organoids in a convenient assay-ready format.

Your Method Development Toolbox

ACD/Method Selection Suite is your software assistant for LC and GC method development. When you want to develop methods using Quality by Design (QbD) principles, and make every experiment count, reach for Method Selection Suite to:

• Choose your starting conditions and columns
• Simulate separations under new conditions
• Optimize your chromatography with 1D, 2D, or 3D models
• Predict the retention times of new compounds
• Database successful methods for future use

When it comes to solid dosage formulations, the most common challenge formulators face is poor solubility. In numbers: 70% of drugs in development are poorly soluble.